Citigroup Cuts Becton, Dickinson and Company (NYSE:BDX) Price Target to $232.00

Becton, Dickinson and Company (NYSE:BDX) had its price target trimmed by Citigroup from $233.00 to $232.00 in a research report released on Tuesday, Marketbeat.com reports. The brokerage currently has a buy rating on the medical instruments supplier’s stock.

Several other analysts also recently weighed in on the stock. Bank of America lifted their price target on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a research note on Monday, January 5th. Wall Street Zen lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Jefferies Financial Group upped their target price on Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, December 10th. JPMorgan Chase & Co. cut their price target on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating on the stock in a research note on Tuesday. Finally, Morgan Stanley lifted their price objective on Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Five research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $195.46.

Becton, Dickinson and Company Stock Down 1.5%

NYSE:BDX opened at $177.93 on Tuesday. The company has a market cap of $50.66 billion, a price-to-earnings ratio of 29.03, a price-to-earnings-growth ratio of 2.38 and a beta of 0.25. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $185.02. The company has a current ratio of 1.05, a quick ratio of 0.64 and a debt-to-equity ratio of 0.67. The stock has a fifty day simple moving average of $199.18 and a 200-day simple moving average of $192.25.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, topping the consensus estimate of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The company had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.15 billion. During the same quarter last year, the firm posted $3.43 EPS. The firm’s revenue was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company announced that its Board of Directors has authorized a share repurchase program on Tuesday, January 27th that authorizes the company to buyback $10.00 million in shares. This buyback authorization authorizes the medical instruments supplier to repurchase up to 0% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be paid a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is 68.52%.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the transaction, the executive vice president owned 12,095 shares in the company, valued at $2,509,228.70. The trade was a 11.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 2,463 shares of company stock valued at $501,530 in the last 90 days. 0.40% of the stock is owned by insiders.

Institutional Trading of Becton, Dickinson and Company

Institutional investors have recently modified their holdings of the company. Brighton Jones LLC grew its stake in shares of Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares in the last quarter. RiverGlades Family Offices LLC purchased a new stake in Becton, Dickinson and Company during the 2nd quarter worth about $344,000. Oppenheimer Asset Management Inc. boosted its position in shares of Becton, Dickinson and Company by 71.4% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 82,655 shares of the medical instruments supplier’s stock worth $15,471,000 after acquiring an additional 34,437 shares in the last quarter. Transcend Capital Advisors LLC increased its holdings in shares of Becton, Dickinson and Company by 88.2% in the 3rd quarter. Transcend Capital Advisors LLC now owns 5,794 shares of the medical instruments supplier’s stock valued at $1,084,000 after acquiring an additional 2,715 shares during the last quarter. Finally, Belpointe Asset Management LLC acquired a new stake in shares of Becton, Dickinson and Company during the 3rd quarter worth about $650,000. 86.97% of the stock is currently owned by institutional investors.

Key Becton, Dickinson and Company News

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Jefferies upgraded BDX to a Buy, providing direct bullish pressure that can support the stock as investors reframe valuation vs. the new pure‑play MedTech focus. Becton Dickinson (BDX) Gets a Buy from Jefferies
• Positive Sentiment: BD completed its Biosciences & Diagnostics spin‑off and merged that business with Waters, locking in roughly $4B in proceeds and accelerating a pivot to a pure‑play MedTech company — a structural catalyst for longer‑term re‑rating. BD Merges Biosciences & Diagnostics Business With Waters
• Positive Sentiment: Q4 results and commentary showed a sales surprise and management highlighted portfolio reshaping and product investments that offset tariff headwinds — supportive for medium‑term margin recovery expectations. BDX Q4 Deep Dive: Portfolio Reshaping and Product Investments Offset Tariff Headwinds
• Positive Sentiment: High‑profile bullish commentary (e.g., Jim Cramer) is adding retail investor interest and narrative support for the “new company” story after the restructuring. Jim Cramer on Becton, Dickinson: “I kind of really like the new company”
• Neutral Sentiment: TD Cowen nudged its price target to $189 from $183 but kept a Hold rating — a modest signal that sentiment is mixed, offering limited near‑term directional impact. TD Cowen Adjusts Becton, Dickinson and Company PT to $189 from $183; Maintains Hold Rating
• Negative Sentiment: Multiple large banks issued pessimistic forecasts or analyst downgrades (JPMorgan, Wells Fargo), increasing selling pressure and contributing to the morning gap down. JPMorgan Chase & Co. Issues Pessimistic Forecast for Becton, Dickinson and Company (NYSE:BDX) Stock Price
• Negative Sentiment: Wells Fargo’s pessimistic outlook added to the analyst sell‑side momentum and volatility pressure. Wells Fargo & Company Issues Pessimistic Forecast for Becton, Dickinson and Company (NYSE:BDX) Stock Price
• Negative Sentiment: Citigroup trimmed its price target (publication notes a lower target), and at least one downgrade produced an early‑session gap down — clear near‑term negatives despite the firm’s longer‑term cash/reshaping positives. Citigroup Lowers Becton, Dickinson and Company (NYSE:BDX) Price Target to $232.00
• Negative Sentiment: Coverage notes that BDX shares gapped down on an analyst downgrade, signalling immediate selling pressure and higher intraday volume as investors digest mixed signals. Becton, Dickinson and Company (NYSE:BDX) Shares Gap Down on Analyst Downgrade

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.